Literature DB >> 12072543

Geographical variation in the penetrance of CDKN2A mutations for melanoma.

D Timothy Bishop1, Florence Demenais, Alisa M Goldstein, Wilma Bergman, Julia Newton Bishop, Brigitte Bressac-de Paillerets, Agnès Chompret, Paola Ghiorzo, Nelleke Gruis, Johan Hansson, Mark Harland, Nicholas Hayward, Elizabeth A Holland, Graham J Mann, Michela Mantelli, Derek Nancarrow, Anton Platz, Margaret A Tucker.   

Abstract

BACKGROUND: Germline mutations in the CDKN2A gene, which encodes two proteins (p16INK4A and p14ARF), are the most common cause of inherited susceptibility to melanoma. We examined the penetrance of such mutations using data from eight groups from Europe, Australia and the United States that are part of The Melanoma Genetics Consortium.
METHODS: We analyzed 80 families with documented CDKN2A mutations and multiple cases of cutaneous melanoma. We modeled penetrance for melanoma using a logistic regression model incorporating survival analysis. Hypothesis testing was based on likelihood ratio tests. Covariates included gender, alterations in p14ARF protein, and population melanoma incidence rates. All statistical tests were two-sided.
RESULTS: The 80 analyzed families contained 402 melanoma patients, 320 of whom were tested for mutations and 291 were mutation carriers. We also tested 713 unaffected family members for mutations and 194 were carriers. Overall, CDKN2A mutation penetrance was estimated to be 0.30 (95% confidence interval (CI) = 0.12 to 0.62) by age 50 years and 0.67 (95% CI = 0.31 to 0.96) by age 80 years. Penetrance was not statistically significantly modified by gender or by whether the CDKN2A mutation altered p14ARF protein. However, there was a statistically significant effect of residing in a location with a high population incidence rate of melanoma (P =.003). By age 50 years CDKN2A mutation penetrance reached 0.13 in Europe, 0.50 in the United States, and 0.32 in Australia; by age 80 years it was 0.58 in Europe, 0.76 in the United States, and 0.91 in Australia.
CONCLUSIONS: This study, which gives the most informed estimates of CDKN2A mutation penetrance available, indicates that the penetrance varies with melanoma population incidence rates. Thus, the same factors that affect population incidence of melanoma may also mediate CDKN2A penetrance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072543     DOI: 10.1093/jnci/94.12.894

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  123 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Localization of a novel melanoma susceptibility locus to 1p22.

Authors:  Elizabeth Gillanders; Suh-Hang Hank Juo; Elizabeth A Holland; MaryPat Jones; Derek Nancarrow; Diana Freas-Lutz; Raman Sood; Naeun Park; Mezbah Faruque; Carol Markey; Richard F Kefford; Jane Palmer; Wilma Bergman; D Timothy Bishop; Margaret A Tucker; Brigitte Bressac-de Paillerets; Johan Hansson; Mitchell Stark; Nelleke Gruis; Julia Newton Bishop; Alisa M Goldstein; Joan E Bailey-Wilson; Graham J Mann; Nicholas Hayward; Jeffrey Trent
Journal:  Am J Hum Genet       Date:  2003-07-03       Impact factor: 11.025

3.  High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families.

Authors:  Marko Hocevar; Magdalena Avbelj; Barbara Perić; Janez Zgajnar; Nikola Besić; Tadej Battelino
Journal:  Croat Med J       Date:  2006-12       Impact factor: 1.351

Review 4.  Clinical applications of melanoma genetics.

Authors:  Michele Gabree; Devanshi Patel; Linda Rodgers
Journal:  Curr Treat Options Oncol       Date:  2014-06

5.  CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Chaffee; Samuel O Antwi; Leon Raskin; Olufunmilayo I Olopade; Donghui Li; W Edward Highsmith; Gerardo Colon-Otero; Lauren G Khanna; Jennifer B Permuth; Janet E Olson; Harold Frucht; Jeanine Genkinger; Wei Zheng; William J Blot; Lang Wu; Luciana L Almada; Martin E Fernandez-Zapico; Hugues Sicotte; Katrina S Pedersen; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

6.  Perceived risk following melanoma genetic testing: a 2-year prospective study distinguishing subjective estimates from recall.

Authors:  Lisa G Aspinwall; Jennifer M Taber; Wendy Kohlmann; Samantha L Leaf; Sancy A Leachman
Journal:  J Genet Couns       Date:  2013-12-10       Impact factor: 2.537

7.  LINE-1 methylation in peripheral blood and the risk of melanoma in melanoma-prone families with and without CDKN2A mutations.

Authors:  Paula L Hyland; Laura S Burke; Ruth M Pfeiffer; Lisa Mirabello; Margaret A Tucker; Alisa M Goldstein; Xiaohong R Yang
Journal:  Melanoma Res       Date:  2013-02       Impact factor: 3.599

8.  Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.

Authors:  Juliette Delaunay; Ludovic Martin; Brigitte Bressac-de Paillerets; Gerard Duru; Olivier Ingster; Luc Thomas
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

Review 9.  Chemoprevention of melanoma.

Authors:  Marie-France Demierre; Glenn Merlino
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 10.  Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.

Authors:  Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng
Journal:  Nat Rev Clin Oncol       Date:  2013-03-26       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.